|
|
|
|
|
|
|
The 2026 Advanced Prostate Cancer Consensus Conference
|
|
|
|
|
|
|
|
Survey Results on Prostate Cancer Management Treatment Preferences in South Asia
|
|
Vedang Murthy, MD, DNB, DipEPP
|
| Vedang Murthy describes the Indian approach to prostate cancer care. He outlines four practical principles guiding treatment decisions in resource-constrained settings: treating as if there is no second chance, preferring simplicity over complexity, prioritizing feasibility, and treating logistics as a clinical variable.
|
|
|
|
|
|
|
|
|
|
| How to Address Inequalities in Access Driven by Lack of Specialist Knowledge
|
| Stacy Loeb, MD, MSc, PhD (Hon)
|
| Stacy Loeb argued that major disparities in prostate cancer care often come from preventable specialist knowledge gaps, especially in germline testing and treatment intensification. She highlighted the IMPLEMENT study as a model for identifying barriers by specialty and setting, then co-creating practical solutions like decision-support tools, cross-specialty tumor boards, and case-based learning to improve guideline-concordant care.
|
|
|
|
|
|
| Is There a Possibility to Make NGS Testing/results Widely Available?
|
| Colin Pritchard, MD, PhD
|
| Colin Pritchard said widely available NGS testing is possible, but only if testing is treated as a supported diagnostic process rather than a simple lab add-on. He emphasized that the path forward is better coverage, education, in-house “pull” workflows with pathology leadership, and molecular tumor boards to make germline, tumor, and liquid biopsy results usable in routine care.
|
|
|
|
|
|
| Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Results After 5 Rounds of PSA Screening (The IMPACT Study)
|
| Rosalind Eeles, PhD, FRCP, FRCR
|
| Ros Eeles presented 5-round IMPACT data showing that annual PSA screening in BRCA2 pathogenic variant carriers detects more clinically significant prostate cancer than in non-carriers, and often at a younger age. The study also found that BRCA1 and BRCA2 carriers were more likely to have unfavorable-risk disease, supporting systematic PSA screening for BRCA2 carriers and consideration of screening for BRCA1 carriers.
|
|
|
|
|
|
| Circulating Biomarkers for Prostate Cancer Precision Medicine - What Will Become Relevant in Daily Clinical Practice Soon?
|
| Gerhardt Attard, MD, PhD, FRCP
|
| Gerhardt Attard said the circulating biomarkers most likely to matter soon in daily prostate cancer practice are serum PSA and plasma DNA/ctDNA. He emphasized that ctDNA is most useful when tied to an actionable treatment target, especially BRCA1/2, MSI/dMMR/TMB-high, and that plasma testing should complement, not replace, tissue and germline testing.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nutritional Counseling for Prostate Cancer Patients Receiving Systemic Therapy
|
|
Maria De Santis, MD, PhD
|
| Maria De Santis outlines nutritional management for prostate cancer patients on systemic therapy. ADT causes fat mass increase, muscle loss, insulin resistance, and fatigue, making body composition assessment more informative than weight alone.
|
|
|
|
|
|
|
|
|
|
| Practical Recommendations for Nutrition in Patients Starting on Long-Term Systemic Therapies
|
| Maria De Santis, MD, PhD
|
| Maria De Santis emphasized that nutrition for men starting long-term ADT should focus on muscle preservation, metabolic health, and quality of life—not just weight loss. She recommended combining diet with exercise, favoring practical low-carbohydrate approaches over extreme diets, and noting that total calorie intake and protein plus resistance training matter most.
|
|
|
|
|
|
|
|
|
|
|
